Fig. 5: STAT6 mutations and 18q gains in BCL2 translocation-negative lFL. | Leukemia

Fig. 5: STAT6 mutations and 18q gains in BCL2 translocation-negative lFL.

From: Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms

Fig. 5

mRNA expression of the anti-apoptotic genes BCL2 and BCL2L1 in relationship to the underlying STAT6 mutation status in BCL2 translocation-negative (BCL2-) lFL did not show any differences in STAT6 wildtype (WT) or mutant (MUT) samples (A). Gains in chromosome 18q21 (including the BCL2 locus) were associated with decreased progression-free survival (PFS) in the patient cohort of lFL as illustrated by Kaplan–Meier plot (B). Time to event variables were analysed with Cox proportional hazards regression. The p-values indicated in the Kaplan–Meier plots were calculated with the log-rank test.

Back to article page